(SLNO) Soleno Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.763m USD | Total Return: -28.3% in 12m
Avg Turnover: 78.2M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Altman Z'' -1.54 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
Soleno Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases. Based in Redwood City, California, the firm’s primary focus is the development and commercialization of VYKAT XR, an extended-release tablet designed to treat Prader-Willi Syndrome, a complex genetic disorder characterized by life-threatening hyperphagia.
Operating within the biotechnology sector, Soleno utilizes an orphan drug development model, which often benefits from regulatory incentives such as extended market exclusivity and tax credits for clinical testing. The company transitioned from its previous identity as Capnia, Inc. in 2017 to concentrate specifically on rare disease therapeutics.
Investors can find further fundamental data and risk assessments for this stock on ValueRay. Given the high capital intensity of the biotech industry, Soleno’s valuation remains closely tied to the regulatory approval timeline and clinical trial outcomes of its lead candidate.
- FDA approval decision for DCCR in Prader-Willi Syndrome treatment
- Commercial launch execution of VYKAT XR impacts long-term revenue growth
- Expansion of orphan drug market share drives valuation multiples
- Future research and development expenses increase capital requirements
- Regulatory exclusivity period protects competitive moat for lead product candidate
| Net Income: 96.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA 45.50 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA 0.17 > 3% & CFO 105.7m > Net Income 96.0m |
| Net Debt (-201.9m) to EBITDA (102.6m): -1.97 < 3 |
| Current Ratio: 5.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (53.1m) vs 12m ago 14.92% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 61.52% > 50% (prev 0.0%; Δ 61.52% > 0%) |
| Interest Coverage Ratio: 18.59 > 6 (EBITDA TTM 102.6m / Interest Expense TTM 5.41m) |
| A: 0.44 (Total Current Assets 326.4m - Total Current Liabilities 58.0m) / Total Assets 608.4m |
| B: -0.66 (Retained Earnings -400.0m / Total Assets 608.4m) |
| C: 0.22 (EBIT TTM 100.5m / Avg Total Assets 463.2m) |
| D: -3.57 (Book Value of Equity -401.8m / Total Liabilities 112.6m) |
| Altman-Z'' = -1.54 = D |
As of May 24, 2026, the stock is trading at USD 53.01 with a total of 0 shares traded.
Over the past week, the price has changed by +0.13%,
over one month by +0.49%,
over three months by +33.69% and
over the past year by -28.26%.
Soleno Therapeutics has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy SLNO.
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 53 | -0% |
P/E Forward = 13.1234
P/S = 9.6941
P/B = 5.5726
Revenue TTM = 285.0m USD
EBIT TTM = 100.5m USD
EBITDA TTM = 102.6m USD
Long Term Debt = 49.9m USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.16m USD (from shortTermDebt, last quarter)
Debt = 53.7m USD (corrected: LT Debt 49.9m + ST Debt 1.16m) + Leases 2.69m
Net Debt = -201.9m USD (calculated: Debt 53.7m - CCE 255.6m)
Enterprise Value = 2.56b USD (2.76b + Debt 53.7m - CCE 255.6m)
Interest Coverage Ratio = 18.59 (Ebit TTM 100.5m / Interest Expense TTM 5.41m)
EV/FCF = 24.25x (Enterprise Value 2.56b / FCF TTM 105.6m)
FCF Yield = 4.12% (FCF TTM 105.6m / Enterprise Value 2.56b)
FCF Margin = 37.05% (FCF TTM 105.6m / Revenue TTM 285.0m)
Net Margin = 33.70% (Net Income TTM 96.0m / Revenue TTM 285.0m)
Gross Margin = unknown ((Revenue TTM 285.0m - Cost of Revenue TTM 3.90m) / Revenue TTM)
Tobins Q-Ratio = 4.21 (Enterprise Value 2.56b / Total Assets 608.4m)
Interest Expense / Debt = 10.07% (Interest Expense 5.41m / Debt 53.7m)
Taxrate = 10.13% (3.54m / 34.9m)
NOPAT = 90.4m (EBIT 100.5m * (1 - 10.13%))
Current Ratio = 5.62 (Total Current Assets 326.4m / Total Current Liabilities 58.0m)
Debt / Equity = 0.11 (Debt 53.7m / totalStockholderEquity, last quarter 495.8m)
Debt / EBITDA = -1.97 (Net Debt -201.9m / EBITDA 102.6m)
Debt / FCF = -1.91 (Net Debt -201.9m / FCF TTM 105.6m)
Total Stockholder Equity = 420.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 20.73% (Net Income 96.0m / Total Assets 608.4m)
RoE = 11.71% (Net Income TTM 96.0m / Total Stockholder Equity 820.2m)
RoCE = 11.56% (EBIT 100.5m / Capital Employed (Equity 820.2m + L.T.Debt 49.9m))
RoIC = 16.38% (NOPAT 90.4m / Invested Capital 551.5m)
WACC = 9.44% (E(2.76b)/V(2.82b) * Re(9.45%) + D(53.7m)/V(2.82b) * Rd(10.07%) * (1-Tc(0.10)))
Discount Rate = 9.45% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 36.50%
[DCF] Terminal Value 71.70% ; FCFF base≈105.6m ; Y1≈106.0m ; Y5≈112.3m
[DCF] Fair Price = 32.14 (EV 1.47b - Net Debt -201.9m = Equity 1.68b / Shares 52.1m; r=9.44% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.16 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.13 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.93 | Chg30d=-0.39% | Revisions=-43% | Analysts=8
EPS next Quarter (2026-09-30): EPS=1.06 | Chg30d=+0.00% | Revisions=-50% | Analysts=8
EPS current Year (2026-12-31): EPS=3.89 | Chg30d=-1.44% | Revisions=-50% | GrowthEPS=+897.8% | GrowthRev=+143.9%
EPS next Year (2027-12-31): EPS=6.06 | Chg30d=-3.65% | Revisions=-50% | GrowthEPS=+55.6% | GrowthRev=+44.4%
[Analyst] Revisions Ratio: -50%